Login
Who's Online
We have 108 guests and no members online
Statistics
- Users 5524
- Articles 732
- Articles View Hits 17034853
Why Use This Site for Advertisement?
Thank you for your interest in advertising on Gene Therapy Net. The website is active since January 2008 and the site's traffic grows day by day (see statistics). The visitors of Gene Therapy Net are professionals, doctors and researchers, as well as students, patients, regulatory affairs officers, government policy officers, and everyone else interested in gene therapy. |
|
Gene Therapy Net is run by a policy officer in the clinical gene therapy trial assessment procedure in the Netherlands. He has a scientific background in molecular biology and immunology. The website is a non-governmental, personal initiative and is aimed to provide comprehensive and accurate information about gene therapy, clinical trials, research news, and relevant gene therapy regulation and legislation. |
Advertisement Opportunities
Full banners, cube banners and text ads will be placed on highly visible sections throughout the site. Cube banners and text ads are placed in the left columns of the site, whereas full banners are placed in the middle wide column of the site. Your banner or text ad will be hyperlinked to the web address of your choice.
There are four different types of campaigns:
1 | Full banner | Located in rotation with other banners on all pages, including the home page |
2 | Home page banner or text links | Located only on the home page. Always visible in 1st or 2nd news item in center of the home page |
3 | Cube banner | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
4 | Text links | Located on left ‘related links’ column on a minimum of 50% of all pages, including the home page |
Advertisement Rates
We suggest a minimum of 3 months or at least 10,000 impressions, but please keep in mind that these rates and time lengths are not set in stone, but rather displayed to give you an idea on how our ad pricing is usually structured. By advertising on Gene Therapy Net, you agree to our terms and conditions listed below.
Contact us for more information about advertising.
Advertising Terms and Conditions: All ads are reviewed for correct usage, and must be approved prior to publication. Gene Therapy Net reserves the right to refuse advertising privileges to any web site for any reason, including the promotion of pornographic products and/or content, the advocating of illegal activities, immoral conduct, plagiarism, cheating, etc. Gene Therapy Net shall not be held responsible for grammatical errors, typographical errors, or errors in artwork provided by the advertiser. All ads are at the discretion of Gene Therapy Net. All rates are agreed on before advertisement is placed. Your ad will be place after full payment has been received. When an order has been received and payment taken for the service there will be no refund to the advertiser. Gene Therapy Net reserves the right to modify, change or otherwise improve upon the design and format of any or all of its pages at any time without notice. Gene Therapy Net reserves the right to modify, eradicate and/or change any or all of these terms and conditions without notice, including the right to change the above rates or to terminate this advertising program. We appreciate, but do not require, reciprocal links to Gene Therapy Net to be posted on your site.
Suggestions
Gene Therapy News
- A sickle cell cure exists. But patients need more than just gene therapy. - PharmaVoice
Fri, 01 Nov 2024 13:44:5 GMT - Roche will aim to tackle gene therapy challenges through Dyno deal - The Pharma Letter
Fri, 01 Nov 2024 13:11:5 GMT - Family raises money for son's gene therapy and clinical trial to treat rare genetic mutation - CBS Los Angeles
Fri, 01 Nov 2024 04:36:0 GMT - University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first - The Business Journals
Fri, 01 Nov 2024 00:14:0 GMT - BioFuture 2024: FDA eases the way for cell and gene therapy companies - BioWorld Online
Thu, 31 Oct 2024 17:00:0 GMT - Capsida’s investigational epilepsy gene therapy gets orphan status - BioWorld Online
Thu, 31 Oct 2024 16:39:4 GMT - Hemophilia B: Gene Therapy Shows Promise - Medscape
Thu, 31 Oct 2024 13:20:1 GMT - Lexeo shares early data on Alzheimer’s gene therapy - Endpoints News
Wed, 30 Oct 2024 20:29:0 GMT - Around the Helix: Cell and Gene Therapy Company Updates – October 30, 2024 - CGTLive™
Wed, 30 Oct 2024 20:11:4 GMT - 12-Year-Old Leaves Washington DC Hospital As The First Patient To Receive Approved Gene Therapy For Sickle Cell Disease - AfroTech
Wed, 30 Oct 2024 20:08:1 GMT - Lexeo Therapeutics Scores Positive Early Data for APOE4-Alzheimer’s Gene Therapy - Inside Precision Medicine
Wed, 30 Oct 2024 16:05:4 GMT - 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - PharmaVoice
Wed, 30 Oct 2024 15:32:3 GMT - A Year of DMD Gene Therapy Trial Failures - AJMC.com Managed Markets Network
Tue, 29 Oct 2024 21:01:1 GMT - Purespring gene therapy reduces kidney scarring in mice and is stably expressed in pigs - Fierce Biotech
Tue, 29 Oct 2024 17:54:0 GMT - The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP - Neurology Live
Mon, 28 Oct 2024 19:56:1 GMT